|
시장보고서
상품코드
2008803
약물유전체학 시장 보고서 : 기술별, 용도별, 최종사용자별, 지역별(2026-2034년)Pharmacogenomics Market Report by Technology, Application, End User, and Region 2026-2034 |
||||||
세계의 약물유전체학 시장 규모는 2025년에 92억 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 176억 달러에 달하며, 2026-2034년에 CAGR 7.25%로 성장할 것으로 예측하고 있습니다.
약물유전체학은 특정 약물에 대한 반응에서 인간 유전자의 유전적 변이를 연구하는 분야입니다. 약리학과 유전체학의 원리를 활용하여 개인의 유전적 구성에 맞는 효과적이고 안전한 의약품을 개발하는 것을 목표로 하고 있습니다. 여기에는 중합효소연쇄반응(PCR), 마이크로어레이, 데옥시리보핵산(DNA) 시퀀싱, 질량분석, 전기영동 등 다양한 기술이 사용됩니다. 약물유전체학에서 이루어지는 유전자 검사는 특정 질병에 대한 감수성이나 신약 개발 약물의 효능을 판단하는 데 도움이 됩니다. 또한 약물유전체학은 심혈관 질환, 알츠하이머병, 암, 인간면역결핍바이러스 및 후천성면역결핍증후군(HIV/AIDS), 천식 등 다양한 질환의 치료에도 폭넓게 활용되고 있습니다.
파마코게놈 시장 동향:
글로벌 제약 산업의 괄목할 만한 성장은 시장의 밝은 전망을 만드는 주요 요인 중 하나입니다. 또한 의약품의 안전성이 개선된 정밀의료에 대한 수요 증가가 시장 성장을 촉진하고 있습니다. 생활습관병의 유병률이 증가함에 따라 부작용을 최소화하고 효능을 높인 표적 약물요법이 널리 채택되고 있습니다. 이에 따라 약물유전체학은 암 치료에도 널리 활용되고 있으며, 화학요법제나 표적 면역생물제제의 약물 반응, 내성, 효능, 독성을 예측하는 데 도움을 주고 있으며, 이 또한 시장 성장에 기여하고 있습니다. 또한 약물유전체학 및 바이오마커 표지 솔루션 개발 등 다양한 기술 발전도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 이는 체내에서 발생할 수 있는 피할 수 있는 약물 부작용(ADR)의 위험을 최소화하고 임상 결과를 개선하는 데 도움이 됩니다. 또한 광범위한 연구개발(R&D) 활동과 헬스케어 인프라의 대폭적인 개선 등 다른 요인들도 시장 성장을 촉진할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 약물유전체학 시장
제6장 시장 내역 : 기술별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.04.30The global pharmacogenomics market size reached USD 9.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 17.6 Billion by 2034, exhibiting a growth rate (CAGR) of 7.25% during 2026-2034.
Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.
PHARMACOGENOMICS MARKET TRENDS:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.
KEY MARKET SEGMENTATION:
Breakup by Technology:
- Polymerase Chain Reaction
- Microarray
- DNA Sequencing
- Mass Spectrometry
- Electrophoresis
- Others
Breakup by Application:
- Oncology
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Diseases
- Psychiatry
- Pain Management
- Others
Breakup by End User:
- Hospitals and Clinics
- Academic and Research Institutes
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. How big is the pharmacogenomics market?
2. What is the future outlook of pharmacogenomics market?
3. What are the key factors driving the pharmacogenomics market?
4. Which are the leading companies in the global pharmacogenomics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Pharmacogenomics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Technology
- 6.1 Polymerase Chain Reaction
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Microarray
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 DNA Sequencing
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Mass Spectrometry
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Electrophoresis
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Application
- 7.1 Oncology
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Infectious Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Cardiovascular Diseases
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Neurological Diseases
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Psychiatry
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Pain Management
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Others
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals and Clinics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Academic and Research Institutes
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 AstraZeneca plc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bayer AG
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Becton Dickinson and Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Bio-Rad Laboratories Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 F. Hoffmann-La Roche AG
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 SWOT Analysis
- 14.3.7 GlaxoSmithKline plc
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Illumina Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Johnson & Johnson
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Merck KGaA
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Myriad Genetics Inc.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Qiagen N.V.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.13 Thermo Fisher Scientific Inc
- 14.3.13.1 Company Overview
- 14.3.13.2 Product Portfolio
- 14.3.13.3 Financials
- 14.3.13.4 SWOT Analysis
- 14.3.1 Abbott Laboratories
